Current role of beta-blockers in the treatment of hypertension

Expert Opinion on Pharmacotherapy

Volumn 11, Issue 16, 2010, Pages 2599-2607

  Aronow, Wilbert S ^a  

^a NEW YORK MEDICAL COLLEGE   (United States)

Author keywords

Antihypertensive drugs; Atenolol; Beta blockers; Carvedilol; Hypertension; Labetalol; Metoprolol; Nebivolol

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; AMLODIPINE; ANGIOTENSIN RECEPTOR ANTAGONIST; ATENOLOL; BENDROFLUMETHIAZIDE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BISOPROLOL; CALCIUM CHANNEL BLOCKING AGENT; CARVEDILOL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; HYDROCHLOROTHIAZIDE; LABETALOL; METOPROLOL; NEBIVOLOL; PERINDOPRIL; PLACEBO; THIAZIDE DIURETIC AGENT; TRANDOLAPRIL; VERAPAMIL;

ACUTE CORONARY SYNDROME; ANGINA PECTORIS; ANTIHYPERTENSIVE THERAPY; AORTA PRESSURE; BLOOD PRESSURE; BLOOD PRESSURE MONITORING; BLOOD PRESSURE REGULATION; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; CORONARY ARTERY BYPASS GRAFT; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DRUG ACTIVITY; DRUG DOSE TITRATION; DRUG EFFECT; DRUG EFFICACY; DRUG INDICATION; DRUG RESEARCH; DRUG USE; DYSLIPIDEMIA; ESSENTIAL TREMOR; FOLLOW UP; GLAUCOMA; HEART ARRHYTHMIA; HEART ATRIUM FIBRILLATION; HEART DEATH; HEART FAILURE; HEART HEMODYNAMICS; HEART INFARCTION; HEART PROTECTION; HEART RATE; HEART VENTRICLE ARRHYTHMIA; HUMAN; HYPERGLYCEMIA; HYPERTENSION; MIGRAINE; ORTHOSTATIC HYPERTENSION; POSTOPERATIVE COMPLICATION; PRACTICE GUIDELINE; PREGNANT WOMAN; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; RISK BENEFIT ANALYSIS; RISK REDUCTION; STROKE; SUPRAVENTRICULAR TACHYCARDIA; THYROTOXICOSIS; TREADMILL EXERCISE; TREATMENT INDICATION;

ADRENERGIC BETA-ANTAGONISTS; AGE FACTORS; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; CARDIOVASCULAR DISEASES; HUMANS; HYPERTENSION; PRACTICE GUIDELINES AS TOPIC;

EID: 78049382771     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.2010.482561     Document Type: Review

References (81)

1. Lopez-Sendon J, Swedberg K, McMurray J, et al. Expert consensus document on beta-adrenergic receptor blockers. Eur Heart J 2004;25:1341-62
2. Manrique C, Giles TD, Ferdinand KC, et al. Realities of newer beta-blockers for the management of hypertension. J Clin Hypertens 2009;11:369-75
3. Aronow WS. Might losartan reduce sudden cardiac death in diabetic patients with hypertension? Lancet 2003;362:591-2
4. Carlberg B, Samuelsson O, Lindholm LH. Atenolol in hypertension: is it a wise choice? Lancet 2004;364:1684-9
5. Teo KK, Yusuf S, Furberg CD. Effects of prophylactic antiarrhythmic drug therapy in acute myocardial infarction. An overview of results from randomized controlled trials. JAMA 1993;270:1589-95
6. Hansteen V. Beta blockade after myocardial infarction: the Norwegian Propranolol Study in high-risk patients. Circulation 1983;67(Suppl 1):57-60
7. Hjalmarson A, Elmfeldt D, Herlitz J, et al. Effect on mortality of metoprolol in acute myocardial infarction. Lancet 1981;2:823-7
8. Gundersen T, Abrahamsen AM, Kjekshus J, et al. Timolol-related reduction in mortality and reinfarction in patients ages 65-75 years surviving acute myocardial infarction. Circulation 1982;66:1179-84
9. Beta-Blocker Heart Attack Trial Research Group. A randomized trial of propranolol in patients with acute myocardial infarction. JAMA 1982;247:1707-14
10. The CAPRICORN Investigators. Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomised trial. Lancet 2001;357:1385-90
11. Park KC, Forman DE, Wei JY. Utility of beta-blockade treatment for older postinfarction patients. J Am Geriatr Soc 1995;43:751-5
12. Yusuf S, Wittes J, Probstfield J. Evaluating effects of treatment subgroups of patients within a clinical trial: the case of non-Q-wave myocardial infarction and beta-blockers. Am J Cardiol 1990;60:220-2
13. Soumerai SB, McLaughlin TJ, Spiegelman D, et al. Adverse outcomes of underuse of beta-blockers in elderly survivors of acute myocardial infarction. JAMA 1997;277:115-21
14. Aronow WS, Ahn C, Kronzon I. Effect of beta-blockers alone, of angiotensin-converting enzyme inhibitors alone, and of beta-blockers plus angiotensin-converting enzyme inhibitors on new coronary events and on congestive heart failure in older persons with healed myocardial infarcts and asymptomatic left ventricular systolic dysfunction. Am J Cardiol 2001;88:1298-300
15. Aronow WS, Ahn C. Incidence of new coronary events in older persons with prior myocardial infarction and systemic hypertension treated with beta-blockers, angiotensin-converting enzyme inhibitors, diuretics, calcium antagonists, and alpha blockers. Am J Cardiol 2002;89:1207-9
16. Cucherat M. Quantitative relationship between resting heart rate reduction and magnitude of clinical benefits in post-myocardial infarction: a meta-regression of randomized clinical trials. Eur Heart J 2007;28:3012-19
17. Smith SC Jr, Blair SN, Bonow RO, et al. AHA/ACC guidelines for preventing heart attack and death in patients with atherosclerotic cardiovascular disease: 2001 update. A statement for healthcare professionals from the American Heart Association and the American College of Cardiology. J Am Coll Cardiol 2001;38:1581-3
18. Smith SC Jr, Allen J, Blair SN, et al. ACC/AHA guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update: endorsed by the National Heart, Lung, and Blood Institute. Circulation 2006;113:2363-72
19. Chobanian AV, Bakris GL, Black HR, et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. The JNC 7 Report. JAMA 2003;289:2560-72
20. Mancia G, De Backer G, Dominiczak A, et al. 2007 Guidelines for the management of arterial hypertension. The task force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2007;25:1105-87
21. Mancia G, Laurent S, Agabiti-Rosei E, et al. Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document. J Hypertens 2009;27:2121-58
22. Mancia G. Prevention of risk factors: beta-blockade and hypertension. Eur Heart J 2009;11(Suppl A):3-8
23. Goch A, Banach M, Mikhailidis DP, et al. Endothelial dysfunction in patients with noncomplicated and complicated hypertension. Clin Exp Hypertens 2009;31:20-30
24. Anderson JL, Adams CD, Antman EM, et al. ACC/AHA 2007 guidelines for the management of patients with unstable angina/non-ST-elevation myocardial infarction-Executive Summary. A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to revise the 2002 guidelines for the management of patients with unstable angina/non-ST-elevation myocardial infarction). J Am Coll Cardiol 2007;50:652-726
25. CIBIS-II Investigators and Committees. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. Lancet 1999;353:9-13
26. MERIT-HF Study Group. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet 1999;353:2001-7
27. Packer M, Coats AJS, Fowler MB, et al. Effect of carvedilol on survival in chronic heart failure. N Engl J Med 2001;344:651-8
28. Flather MD, Shibata MC, Coats AJS, et al. Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS). Eur Heart J 2005;26:215-25
29. Aronow WS, Ahn C, Kronzon I. Effect of propranolol versus no propranolol on total mortality plus nonfatal myocardial infarction in older patients with prior myocardial infarction, congestive heart failure, and left ventricular ejection fraction ≥ 40% treated with diuretics plus angiotensin-converting- enzyme inhibitors. Am J Cardiol 1997;80:207-9
30. Houghton T, Freemantle N, Cleland JG. Are beta-blockers effective in patients who develop heart failure soon after myocardial infarction? A meta-regression analysis of randomised trials. Eur J Heart Fail 2000;2:333-40
31. Jessup M, Abraham WT, Casey DE, et al. 2009 focused update: ACCF/AHA guidelines for the diagnosis and management of heart failure in adults. A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Developed in collaboration with the International Society for Heart and Lung Transplantation. J Am Coll Cardiol 2009;53:1343-82
32. Refaat S, El-Ghaffar NA, Negm HAE-R, Yousri T. The role of aldosterone in myocardial dysfunction of Egyptian patients with essential hypertension. Arch Med Sci 2008;4:161-6
33. Cohen-Solal A, Kotecha D, van Velduisen DJ, et al. Efficacy and safety of nebivolol in elderly heart failure patients with impaired renal function: insights from the SENIORS trial. Eur J Heart Fail 2009;11:872-80
34. Kennedy HL, Brooks MM, Barker AH, et al. Beta-blocker therapy in the Cardiac Arrhythmia Suppression Trial. Am J Cardiol 1994;74:674-80
35. Aronow WS, Ahn C, Mercando AD, et al. Effect of propranolol versus no antiarrhythmic drug on sudden cardiac death, total cardiac death, and total death in patients ≥ 62 years of age with heart disease, complex ventricular arrhythmias, and left ventricular ejection fraction ≥ 40%. Am J Cardiol 1994;74:267-70
36. Aronow WS, Banach M. Atrial fibrillation: the new epidemic of the ageing world. J Atrial Fib 2009;1:337-61
37. Gundersen T, Kjekshus J. Timolol treatment after myocardial infarction in diabetic patients. Diabetes Care 1983;6:285-90
38. Malmberg K, Ryden L. Myocardial infarction in patients with diabetes mellitus. Eur Heart J 1988;9:259-64
39. Aronow WS, Ahn C. Effect of beta-blockers on incidence of new coronary events ion older persons with prior myocardial infarction and diabetes mellitus. Am J Cardiol 2001;87:780-1
40. Holman RR, Paul SK, Bethel MA, et al. Long-term follow-up after tight control of blood pressure in type 2 diabetes. N Engl J Med 2008;359:1565-76
41. Bielecka-Dabrowa A, Michalska M, Rysz J, Banach M. Arterial hypertension in patients with coronary artery disease treated with coronary artery bypass surgery. Arch Med Sci 2009;5:S378-92
42. Banach M, Kourliouros A, Reinhart KM, et al. Postoperative atrial fibrillation-what do we really know? Curr Vasc Pharmacol 2010. [Epub ahead ofprint]
43. Dunkelgrun M, Boersma E, Schouten O, et al. Bisoprolol and fluvastatin for the reduction of perioperative cardiac mortality and myocardial infarction in intermediate-risk patients undergoing noncardiopvascular surgery: a randomized controlled trial (DECREASE-IV). Ann Surg 2009;249:921-6
44. Fleischmann KE, Beckman JA, Buller CE, et al. 2009 ACCF/AHA focused update on perioperative beta blockade. A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2009;54:2102-28
45. POISE Study Group. Effects of extended-release metoprolol succinate I patients undergoing non-cardiac surgery (POISE trial): a randomised controlled trial. Lancet 2008;371:1839-47
46. Aronow WS, Frishman WH. Treatment of hypertension and prevention of ischemic stroke. Curr Cardiol Rep 2004;6:124-9
47. Mancia G, Seravalle G, Grassi G. Therapeutic strategies to lower and control high blood pressure. Arch Med Sci 2009;5:S294-9
48. Mancia G, Grassi G, Zanchetti A. New onset diabetes and antihypertensive drugs. J Hypertens 2006;24:3-10
49. Messerli FH, Grossman E, Goldbourt U. Are beta-blockers efficacious as first-line therapy for hypertension in the elderly? A systematic review. JAMA 1998;279:1903-7
50. MRC Working Party. Medical Research Council Trial of treatment of hypertension in older adults: principal results. Br Med J 1992;304:405-12
51. Coope J, Warrender TS. Randomised trial of the treatment of hypertension in elderly patients in primary care. Br Med J 1986;293:1145-51
52. The Dutch TIA Trial Study Group. Trial of secondary prevention with atenolol after transient ischemic attack or nondisabling ischemic stroke. Stroke 1993;24:543-8
53. Erikkson S, Olofsson BO, Wester PO. Atenolol in the secondary prevention after stroke. Cerebrovasc Dis 1995;5:21-5
54. UK Prospective Diabetes Study Group. Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes:UKPDS39. Br Med J 1998;317:713-20
55. Dahlof B, Devereux RB, Kjeldsen SE, et al. Cardiovascular morbidity and mortality in the losartan intervention for endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002;359:995-1003 (Pubitemid 34286536)
56. Wilhelmsen L, Berglund G, Elmfeldt D, et al. Beta-blockers versus diuretics in hypertensive men: main results from the HAPPHY trial. J Hypertens 1987;5:561-72
57. Zanchetti A, Bond MG, Henning M, et al. Calcium antagonist lacidipine slows down progression of asymptomatic carotid atherosclerosis. Principal results of the European lacidipine study on atherosclerosis (ELSA), a randomized, double-blind, long-term trial. Circulation 2002;106:2422-7
58. Pepine CJ, Handberg EM, Cooper-DeHoff RM, et al. A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil-Trandolapril Study (INVEST): a randomized controlled trial. JAMA 2003;290:2805-16
59. Dahlof B, Sever PS, Poulter NR, et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BLPA): a multicentre randomised controlled trial. Lancet 2005;366:895-906
60. Lindholm LH, Carlberg B, Samuelsson O. Should beta-blockers remain first choice in the treatment of primary hypertension? A meta-analysis. Lancet 2005;366:1545-53
61. Blood Pressure Lowering Treatment Trialists' Collaboration. Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials. Lancet 2003;362:1527-35
62. Law MR, Morris JK, Wald NJ. Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies. Br Med J 2009;338:1665-83
63. Morgan T, Lauri J, Bertram D, Anderson A. Effect of different antihypertensive drug classes on central aortic pressure. Am J Hypertens 2004;17:118-23
64. Hirata K, Vlachopoulos C, Adji A, O'Rourke MF. Benefits from angiotensin-converting enzyme inhibitor beyond blood pressure lowering, beyond blood pressure or beyond the brachial artery? J Hypertens 2005;23:551-6
65. London GM, Asmar RG, O'Rourke MF, Safar ME. Mechanism(s) of selective blood pressure reduction after a low-dose combination of perindopril/indapamide in hypertensive subjects: comparison with atenolol. J Am Coll Cardiol 2004;43:92-9
66. Cockcroft JR, Brown MJ. Losartan for cardiovascular disease inpatients with and without diabetes in the LIFE study. Lancet 2002;359:2202-4
67. Kelly R, Daley J, Avolio A, O'Rourke M. Arterial dilation and reduced wave reflection. Benefit of dilevalol in hypertension. Hypertension 1989;14:14-21
68. Wilkinson IB, McEniery CM, Cockcroft JR Atenolol and cardiovascular risk: an issue close to the heart. Lancet 2006;367:627-9
69. Wikstrand J, Kendall M. The role of beta receptor blockade in preventing sudden death. Eur Heart J 1992;12(Suppl D):111-20
70. Wilhelmsen L, Berglund G, Elmfeldt D, et al. Beta-blockers versus diuretics in hypertensive men: main results from the HAPPHY trial. J Hypertens1987;5:561-72
71. Wikstrand J, Warnold I, Olsson G, et al. Primary prevention with metoprolol in patients with hypertension. Mortality results from the MAPHY study. JAMA 1988;259:1976-82
72. Olsson G, Tuomilehto J, Berglund G, et al. Primary prevention of sudden cardiovascular death in hypertensive patients. Mortality results from the MAPHY study. Am J hypertens 1991;4:151-8
73. Bangalore S, Wild D, Parkar S, et al. Beta-blockers for primary prevention of heart failure in patients with hypertension. Insights from a meta-analysis. J Am Coll Cardiol 2008;52:1062-72
74. Nilsson PM. Diabetes and hypertension. Arch Med Sci 2009;5:S310-19
75. Bangalore S, Parkar S, Grossman E, Messerli FH. A meta-analysis of 94,492 patients with hypertension treated with beta-blockers to determine the risk of new-onset diabetes mellitus. Am J Cardiol 2007;100:1254-62
76. Bakris GL, Fonseca V, Katholi RF, et al. Metabolic effects of carvedilol vs metoprolol in patients with type 2 diabetes mellitus and hypertension. A randomized controlled trial. JAMA 2004;292:2227-36
77. Frishman WH. Carvedilol. N Eng J Med 1998;339:1759-65
78. Messerli FH, Grossman E. beta-blockers in hypertension: is carvedilol different? Am J Cardiol 2004;93(Suppl):7-12B
79. Kamp O, Sieswerda GT, Visser CA. Comparison of effects on systolic and diastolic left ventricular function of nebivolol versus atenolol in patients with uncomplicated essential hypertension. Am J Cardiol 2003;92:344-8
80. Kokkinos P, Chrysohoou C, Panagiotakos D, et al. Beta-blockade mitigates exercise blood pressure in hypertensive male patients. J Am Coll Cardiol 2006;47:794-8
81. Sethi A, Arora RR. Ambulatory blood pressure as a predictor of cardiovascular risk. Arch Med Sci 2009;5:S3-9